Business Description
Charles River Laboratories International Inc
NAICS : 541714
SIC : 8732
ISIN : US1598641074
Total Employee Number:
19,700Compare
Compare
Traded in other countries / regions
CRL.USARV6.GermanyCRL.Mexico1CRL.Italy Index Membership
S&P 500Russell 1000Russell 3000 IPO Date
2000-06-23Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 1.07 | |||||
Debt-to-EBITDA | 13.73 | |||||
Interest Coverage | 4.39 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.61 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.5 | |||||
3-Year EBITDA Growth Rate | -24.5 | |||||
3-Year EPS without NRI Growth Rate | -2.6 | |||||
3-Year FCF Growth Rate | 22.1 | |||||
3-Year Book Growth Rate | 3.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.72 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1.72 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.7 | |||||
9-Day RSI | 63.88 | |||||
14-Day RSI | 67.98 | |||||
3-1 Month Momentum % | 32.59 | |||||
6-1 Month Momentum % | 34.7 | |||||
12-1 Month Momentum % | 47.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1.04 | |||||
Cash Ratio | 0.17 | |||||
Days Inventory | 43.03 | |||||
Days Sales Outstanding | 48.54 | |||||
Days Payable | 20.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 2.28 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.67 | |||||
Operating Margin % | 11.66 | |||||
Net Margin % | -5.96 | |||||
EBITDA Margin % | 5.51 | |||||
FCF Margin % | 9.27 | |||||
OCF Margin % | 14.56 | |||||
ROE % | -7.59 | |||||
ROA % | -3.18 | |||||
ROIC % | 6.8 | |||||
3-Year ROIIC % | 25.79 | |||||
ROC (Joel Greenblatt) % | -4 | |||||
ROCE % | -1.21 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 25.69 | |||||
PE Ratio without NRI | 29.44 | |||||
Shiller PE Ratio | 53.27 | |||||
PS Ratio | 3.56 | |||||
PB Ratio | 4.9 | |||||
Price-to-Free-Cash-Flow | 38.42 | |||||
Price-to-Operating-Cash-Flow | 24.49 | |||||
EV-to-EBIT | -217.03 | |||||
EV-to-Forward-EBIT | 43.78 | |||||
EV-to-EBITDA | 76.2 | |||||
EV-to-Forward-EBITDA | 24.83 | |||||
EV-to-Revenue | 4.2 | |||||
EV-to-Forward-Revenue | 4.32 | |||||
EV-to-FCF | 45.33 | |||||
Price-to-GF-Value | 1.5 | |||||
Price-to-Projected-FCF | 2.19 | |||||
Price-to-Median-PS-Value | 1.29 | |||||
Earnings Yield (Greenblatt) % | -0.46 | |||||
FCF Yield % | 2.66 | |||||
Forward Rate of Return (Yacktman) % | -15.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:CRL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Charles River Laboratories International Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,998.987 | ||
| EPS (TTM) ($) | -4.85 | ||
| Beta | 1.3121 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.28 | ||
| Volatility % | 37.52 | ||
| 14-Day RSI | 67.98 | ||
| 14-Day ATR ($) | 9.821957 | ||
| 20-Day SMA ($) | 279.255 | ||
| 12-1 Month Momentum % | 47.3 | ||
| 52-Week Range ($) | 144.26 - 303.305 | ||
| Shares Outstanding (Mil) | 47.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Charles River Laboratories International Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Charles River Laboratories International Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-18 08:30 | In 174 days | ||
| Annual report for 2026 | 2027-02-18 | In 173 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-18 | In 173 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 09:00 | In 69 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 68 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 09:00 | 234.12 (-0.09%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 234.12 (-0.09%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 174.79 (-2.35%) | ||
| William Blair and Jefferies Conferences | 2026-06-02 11:00 | 182.07 (+0.99%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 181.73 (-2.94%) |
Show
Entries
Charles River Laboratories International Inc Frequently Asked Questions
What is Charles River Laboratories International Inc(CRL)'s stock price today?
The current price of CRL is $291.50. The 52 week high of CRL is $303.31 and 52 week low is $144.26.
When is next earnings date of Charles River Laboratories International Inc(CRL)?
The next earnings date of Charles River Laboratories International Inc(CRL) is 2026-11-05 Est..
Does Charles River Laboratories International Inc(CRL) pay dividends? If so, how much?
Charles River Laboratories International Inc(CRL) does not pay dividend.
Guru Commentaries on NYSE:CRL
Madison Small Cap Fund
Bullish
2025 Q3
What the manager wrote
We initiated a position in Charles River Labs in Q3. CRL is a high-quality company in the drug discovery and development outsourcing space with a broad range of services from basic research to contract manufacturing. The company has operating margins of 20% or more and generates substantial free cash flow. The customer base is diverse and CRL benefits from the increased dynamics of outsourcing by its biopharmaceutical clients. We believe Charles River’s earnings power can reach approximately $15 in 2028, assuming modest growth. We also use a sum of the parts at ~12x EBITDA to assess the attractiveness of CRL, implying an intrinsic value of $228.
Press Release
Articles on Charles River Laboratories International Inc
John Rogers Trims Sphere Entertainment Co (SPHR) -- Stock Still 106% Overvalued on GF Value
Aug 21, 2026
John Rogers Trims Madison Square Garden Entertainment Corp (MSGE) Stake as Shares Trade 77% Above GF Value
Aug 21, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers